{"id":"NCT01499134","sponsor":"Thomas Jefferson University","briefTitle":"Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure","officialTitle":"Effect of Nebivolol Compared With Metoprolol in Hypertensive Patients With Peripheral Arterial Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2011-12-26","resultsPosted":"2014-12-03","lastUpdate":"2014-12-17"},"enrollment":17,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Peripheral Artery Disease","Hypertension"],"interventions":[{"type":"DRUG","name":"nebivolol","otherNames":["Bystolic"]},{"type":"DRUG","name":"Metoprolol succinate","otherNames":["Toprol XL"]}],"arms":[{"label":"nebivolol","type":"EXPERIMENTAL"},{"label":"metoprolol succinate","type":"ACTIVE_COMPARATOR"}],"summary":"This is a 26-week, prospective double-blind, randomized pilot trial of nebivolol versus an active control, metoprolol succinate, in patients with established lower-extremity peripheral artery disease, hypertension, and at least moderate risk for coronary artery disease.","primaryOutcome":{"measure":"Peak Walking Time (PWT)","timeFrame":"Baseline PWT is measured at the time of enrollment and again at the final study visit at 26 weeks.","effectByArm":[{"arm":"Nebivolol","deltaMin":110.4,"sd":89.7},{"arm":"Metoprolol Succinate","deltaMin":-19.4,"sd":110.8}],"pValues":[{"comp":"OG000 vs OG001","p":"0.039"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":9},"commonTop":[]}}